HOME         WEBSITE         SUBSCRIBE           E-GREETINGS   
                               

Wednesday, February 25, 2015

Chemicals & Fertilizers Minister assures Pharmaceutical Industry of reforms to make India self-sufficient in Bulk Drugs

“2015 – Year of Active Pharmaceutical Ingredients” launched 

The Union Minister of Chemicals & Fertilizers Sh. Ananth Kumar has assured the Pharmaceutical Industry that appropriate decisions will be taken soon so that India becomes self-sufficient in the Bulk Drugs. Speaking at the launch ceremony of “2015 – Year of Active Pharmaceutical Ingredients” he said that the Government is committed to usher in reforms and good governance, and promote the concept of “Make in India”. He said that the Government had set up Katoch Committee to look into various issues concerning the bulk drugs, and its recommendations have been received which will be implemented expeditiously after taking the Cabinet's approval. Sh. Ananth Kumar said that the Bulk Drugs constitute the backbone of the Pharmaceutical Industry and the sector needs to be incentivized so as to take on the challenge from cheap imports. The Minster said that there can be no compromise with the quality, environmental requirements or regulatory necessities but the issues hampering the growth of the industry have to be addressed. He said over-dependence on imports from one country for bulk drugs is detrimental to the country's interest and hence, paradigm shift is necessary. 

Sh. Ananth Kumar said that in formulations, India is a world leader and there is no reason why we should not be in the bulk drugs sector also. He said the Government is committed to support the bulk drug industry and revival of Public Sector Undertakings of the sector is on the anvil. Discussions with State Governments are also going on to solicit their cooperation for setting up Mega Pharma Parks. He called upon the industry to tap the skilled manpower and potential of the country and come up with an action plan for strengthening the Bulk Drugs Sector. 

Speaking on the occasion, Minister of State for Chemicals & Fertilizers Sh. Hansraj Gangaram Ahir said that more research and development activities need to be taken in this sector. He called for industry-government cooperation to give boost to the Bulk Drugs Industry. 

Secretary, Department of Pharmaceuticals Dr. V.K. Subburaj said that there is an urgent need to bring about self-sufficiency in the field of Active Pharmaceutical Ingredients (API). He said that the Government is taking steps to reduce dependence on imports and initiate good policy measures to support the industry. 

India is very much dependent on import from a single source for basic chemicals, intermediates and APIs for many commonly used medicines. To avoid the price and supply risks associated with such situation and ensure assured and sustained availability of these basic inputs to formulation sector, there is a felt need to focus the attention to promote the manufacturing of API in India. This is also consistent with the avowed objective of the government regarding ‘Make in India'. In recognition of the situation, Department of Pharmaceuticals has declared the Year 2015 as the Year of API. The Government will take measures to facilitate the growth of the sector and also interact with the industry on a more regular basis to improve G2B interactions and promote better and more coordinated efforts to achieve the objective of ‘Make in India', especially for the API sector.
Posted by

Blog Archive

____________________________________________________________________________________________

Disclaimer - All investments in Mutual Funds and securities are subject to market risks and uncertainty of dividend distributions and the NAV of schemes may go up or down depending upon factors and forces affecting securities markets generally. The past performance of the schemes is not necessarily indicative of the future performance and may not necessarily provide a basis for comparison with other investments. Investors are advised to go through the respective offer documents before making any investment decisions. Prospective client(s) are advised to go through all comparable products in offer before taking any investment decisions. Mutual Funds and securities investments are subject to market risks and there is no assurance or guarantee that the objectives of the fund will be achieved. Information gathered & material used in this document is believed to be from reliable sources. Decisions based on the information provided on this newsletter/document are for your own account and risk.


In the preparation of the material contained in this document, Varun Vaid has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the Varun Vaid and which may have been made available to Varun Vaid. Information gathered & material used in this document is believed to be from reliable sources. Varun Vaid however does not warrant the accuracy, reasonableness and/or completeness of any information. For data reference to any third party in this material no such party will assume any liability for the same. Varun Vaid does not in any way through this material solicit any offer for purchase, sale or any financial transaction/commodities/products of any financial instrument dealt in this material. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice.


Varun Vaid, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. All recipients of this material should before dealing and/or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. Any person subscribing to or investigating in any product/financial instruments should do soon the basis of and after verifying the terms attached to such product/financial instrument. Financial products and instruments are subject to market risks and yields may fluctuate depending on various factors affecting capital/debt markets. Please note that past performance of the financial products and instruments does not necessarily indicate the future prospects and performance there of. Such past performance may or may not be sustained in future. Varun Vaid, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation in the financial instruments/products/commodities discussed here in or act as advisor or lender / borrower in respect of such securities/financial instruments/products/commodities or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said person may have acted upon and/or in a manner contradictory with the information contained here. No part of this material may be duplicated in whole or in part in any form and or redistributed without the prior written consent of Varun Vaid. This material is strictly confidential to the recipient and should not be reproduced or disseminated to anyone else.


Varun Vaid also does not take any responsibility for the contents of the advertisements published. Readers are advised to verify the contents on their own before acting there upon.


Published Credits goes to following sources & all the mentioned sources as footer below the published material- Bloomberg, Valueresearch Online, Capital Market, Navindia, Franklin Templeton, Kitco, SBI AMC, LIC AMC, JM Financial AMC, HDFC AMC, The Hindu, Business Line, Personal FN, Economic Times, Reuters, Outlook Money, Business Standard, Times of India etc.